Narzędzia do badań onkologicznych dla laboratoriów
Cardio-Oncology Education and Training: JACC Council Perspectives
The development of innovative cancer therapies has led to unprecedented improvement in survival outcomes and diverse treatment-related toxicities, including those with cardiovascular in nature. Aging population further increase the number of patients being treated for cancer, especially those with comorbidities. As existing and developing cardiovascular disease poses some the greatest risk of morbidity and mortality in patients with cancer.
Addressing the needs of complex cardiovascular patients has become increasingly important, which resulted in important for intersecting disciplines: cardio-oncology. Over the past decade, there has been a remarkable improvement of cardio-oncology clinics and service lines. This development, however, has occurred in a vacuum practice guidelines and training standards, although these are being actively pursued. In the document the board’s perspective, the authors describe the scope of practice in oncology and cardio-training requirements proposed, and the core competencies required. This document also serves as a road map to confirm cardio-oncology as a subspecialty of medicine.
The use of biomarkers to guide the selection of patients and therapies have gained a lot of attention to improving the scope and complexity of the selection of targeted therapy and immunotherapy. Clinical trials provide the basis for the discovery of biomarkers, which can then help in the development of new drugs. For that, a sample of cancer patients, including DNA, RNA, proteins, and metabolome isolated from cancerous tissue and blood or urine, is analyzed in a variety of ways to identify relevant biomarkers. In conjunction with the nucleotide-based, high-throughput, next-generation sequencing techniques, therapy-guided tests rely immunohistochemistry biomarker-based proteins play an important role in cancer treatment. In this review, we discuss the current knowledge of DNA and protein biomarkers for cancer immunotherapy.
both the primary and recurrence of cancer in patients after resection of colorectal cancer: An analysis of the integrated test with the Japan Clinical Oncology Group: JCOG1702A
Background: Improved early detection and treatment have resulted in an increase in the number of long-term victims of colorectal cancer (CRC). For the victims, a second primary cancers and recurrences are important issues; However, the evidence for the study of appropriate control strategies limited.This remnants aims to determine the frequency and timing of a second primary cancer in patients after surgery to explore the appropriate control strategies using an integrated analysis of three large-scale randomized controlled trials in Japan.
Methods: The eligibility criteria of the three trials included histologically confirmed CRC and receive operations. Time, location and frequency of second primary cancers and recurrences investigated. risk factors associated with a second primary cancer were also examined. standard incidence ratio (SIR) of a second primary cancer in comparison to the national database of the Cancer Registry of Japan is expected. Results: A total of 2824 patients were included in this study. The cumulative incidence of second primary cancers increased from time to time. SIR of each second primary cancer was 1.07 (95% CI: 0.94 to 1.21). SIR for second primary cancers intestine was 1.09 (95% CI: 0.79 to 1.47). The cumulative incidence of recurrence nearly reached a plateau at 3 years.
Conclusions: A strategy for the general supervision of the general population can be applied even to patients curatively resected CRC, as a second primary cancer risk is nearly the same as the general population.
Cardio-Oncology Education and Training: JACC Council Perspectives
Adherence to Oral Anticancer Therapeutics in Gynecologic Oncology Population
Introduction: To get a better understanding of gynecologic oncology patient compliance with oral anticancer agents through both cross-sectional survey of compliance and qualitative interviews with patients and physicians about their experiences with the drug.
Methods: Participants were eligible completing the survey for this cross-sectional study that included an assessment of compliance, distress, quality of life, and health literacy. Each woman takes oral anticancer agent for gynecological malignancies in a tertiary academic medical center for 30 days or more to qualify. semi-structured qualitative interviews (n = 14) was then performed to explore the experience with oral anticancer agent. We also perform qualitative group interviews with doctors and nurse practitioners.
Results: One hundred women taking oral anticancer agent listed. Fifty-four percent reported perfect adherence to their treatment, 21% reported a vague compliance (indicating at least one nonadherent behavior in the previous 7 days), and 25% reported non-compliance (indicating more than one behavior nonadherent within 7 days in advance). Qualitative analysis identified five main themes: the ease of use compared to traditional therapies; drugs self-administered mental burden; the perceived importance of the drug; management of side effects; and the desire for physician communication consistent. common misperception stated in an interview health care professionals including the high adherence to oral medication and a belief that the cost is the biggest barrier to compliance.
Description: PlGF-3 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-3 is expressed exclusively in the placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-3 lacks heparin binding affinity. Recombinant human PlGF-3 is a 45.7 kDa disulfide-linked homodimeric protein of two 203 amino acid polypeptide chains.
Description: PlGF-1 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PlGF-1 is expressed in placental tissues, colon and mammary carcinomas. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. Recombinant human PlGF-1 is a 29.7 kDa disulfide-linked homodimeric protein of two 132 amino acid polypeptide chains.
Description: PLGF-2 is an angiogenic factor that belongs to the cysteine-knot superfamily of growth factors. PLGF-2 is expressed in umbilical vein endothelial cells and placenta. It signals through the VEGFR-1/FLT1 receptor and stimulates endothelial cell proliferation and migration. PlGF-2 also signals through Neuropilin (NP-1) and can bind with high affinity to heparin. Recombinant human PLGF-2 is a 34.0 kDa disulfide-linked homodimeric protein of two 150 amino acid polypeptide chains.
Description: Placental growth factor(PGF, also known as PLGF) codes for an angiogenic factor expressed in placental tissue that is similar to vascular permeability factor/vascular endothelial growth factor(VPF/VEGF). It is a glycosylated dimeric secreted protein able to stimulate endothelial cell growth in vitro. PGF is located on chromosome 14 and has been conserved in evolution. It belongs to the family of vascular endothelial growth factors(VEGFs) and binds to the flt-1 VEGF receptor. PLGF-2, which is a PLGF isoform, binds neuropilin-1 and 2 in a heparin-dependent manner. PGF regulates inter- and intra molecular cross talk between the VEGF RTKs Flt1 and Flk1 and stimulates the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Moreover, it plays an important role in pathological angiogenic events and with exerting its biological activities through binding to VEGFR1.
Human Antigen Peptide Transporter 2 (TAP2) Peptide
Description: Enzyme-linked immunosorbent assay kit for quantification of Human PLGF in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.
Description: Placenta Growth Factor-2 (PLGF-2) is an angiogenic factor produced in umbilical vein endothelial cells and placenta. PLGF-2 plays important roles in angiogenesis and endothelial cell growth.
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Anti cyclic cirtullinated peptide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: Description of target: The protein, also called PGF, is 149 amino acids long and shares 53% identity with the platelet-derived growth factor-like region of human VPF. And the N-glycosylated PLGF protein is secreted into the medium and that it functions as a dimer1. The PLGF gene is mapped to 14q24-q31. There are 3 isoforms of PGF, designated PGF1, PGF2, and PGF3. Only PGF2 is able to bind heparin. Additionally, PGF regulates inter- and intramolecular cross-talk between the VEGF receptor tyrosine kinases FLT1 and FLK12. It also can stimulate angiogenesis and collateral growth in ischemic heart and limb with at least a comparable efficiency to VEGF3.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 1 pg/mL
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Human anti cyclic citrullinated peptide antibody ELISA kit
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Human anti cyclic citrullinated peptide antibody ELISA kit
Description: A competitive ELISA for quantitative measurement of Human anti cyclic citrullinated peptide antibody in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Human anti-cyclic citrullinated peptide,CCP ELISA Kit
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PlGF . This antibody is tested and proven to work in the following applications:
Conclusion: Nearly half of the patients surveyed reported vague or non-compliance with their oral anticancer agent. Qualitative interviews identified several important themes, many of which are not recognized by physicians and nurse practitioners. These findings highlight the need for the patient and health care professional interventions to improve patient adherence.
